To some market analysts, quiet, expensive stock markets are overlooking speculative activity into products such as bitcoin. » Read More
By: Elizabeth Gurdus
Jim Cramer looks to the stocks and events on his radar next week, including a monumental meeting at Cisco and a key Fed report. » Read More
There are many reasons to buy shares of those chipmakers, but a play on cryptocurrencies is not one of them, Jim Cramer says. » Read More
By: Evelyn Cheng
China's flagship One Belt, One Road program has far from enough financing right now, representatives from Beijing said in New York last week. » Read More
The bull rally may be strong, but the long-term outlook appears weak and uncertain, Vanguard founder Jack Bogle tells CNBC.
CNBC PRO used crowdsourced earnings platform Estimize to find the stocks with the best chance at beating the Street.
International mining giant Freeport-McMoRan is up 104 percent in the past year, but some analysts say it’s still a buy.
Heal is a start-up revolutionizing health care with doctors on call. Today it announces national expansion plans.
Balancing active and passive approaches to portfolio management can deliver the best of both worlds while compensating for any downsides.
Tribune Media, one of the largest U.S. television station operators, said on Tuesday that activist investor Starboard Value had taken a 6.6 percent stake in the company.
TipRanks identified the corporate insiders with the best-performing track record and found out which stocks they like right now.
Barry Rosenstein's Jana Partners has teamed up with former Bulgari boss Francesco Trapani to nab a stake and three board seats.
Buybacks keep rolling along, but here is why they are no panacea for all of the market's problems.
Bloomin' Brands closed 43 stores on Feb. 15, according to the company.
The major U.S. equity indexes weren't the only ones making history on Tuesday.
Shares of Scripps Networks Interactive rose Tuesday, after the company reported a revenue beat for the fourth quarter.
Shares of Apple hit an all-time high Tuesday, setting a fresh record for the second time this year after nearly two years without a new high.
Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration.
Vanguard founder and former CEO Jack Bogle shares his views on the market.
Two popular biotech exchange-traded funds have been on a tear lately, and some strategists see more upside ahead.
Despite a rally that has sent the S&P 500 up a gaudy 5 percent, Goldman is sticking to its fairly pessimistic call for the full year.
Macy's CEO Terry Lundgren sat down with CNBC for an exclusive conversation on what's ahead for the U.S. retailer.
Improving economic data, wider market volume and Trump administration policy expectations are pushing stocks, Mohamed El-Erian says.
The "FANG" stocks could outperform the market by more than 30 percent this year, forecasts the well-known market watcher.
Get the best of CNBC in your inbox